Literature DB >> 13929695

A clinical evaluation of the antiarrhythmic properties of antazoline.

L LEON-SOTOMAYOR.   

Abstract

Entities:  

Keywords:  ANTIHISTAMINICS; MYOCARDIAL DEPRESSANTS

Mesh：

Substances：

Year:  1963        PMID： 13929695     DOI： 10.1016/0002-9149(63)90084-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  6 in total

1.  Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Ilona Kowalik; Marek Konka; Hanna Szwed; Mariusz Pytkowski
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

2.  Antiarrhythmic actions of clemizole as pharmacologic evidence for a circus movement mechanism in atrial flutter.

Authors:  R Mendez; E Kabela; G Pastelin; M Martínez-López; S Sánchez-Pérez
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1969

3.  Antazoline therapy of recurrent refractory supraventricular arrhythmias--a preliminary report.

Authors:  E Downar; M B Waxman
Journal:  Can Med Assoc J       Date:  1975-09-06       Impact factor: 8.262

4.  Antazoline in the treatment of cardiac arrhythmias.

Authors:  S S Shah; C H Vaidya; H V Doshi
Journal:  Postgrad Med J       Date:  1972-05       Impact factor: 2.401

5.  Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart.

Authors:  Bartłomiej Jacek Bińkowski; Marcin Makowski; Paweł Kubiński; Andrzej Lubiński
Journal:  Cardiovasc Drugs Ther       Date:  2018-04       Impact factor: 3.727

6.  Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Rafal Dabrowski; Mariusz Pytkowski; Ilona Kowalik; Hanna Szwed
Journal:  Trials       Date:  2012-09-11       Impact factor: 2.279
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.